Frost has fully develop drug discovery capabilities and specializes in developing new experimental therapeutics with minimal resources. Founded upon a licensed phenotypic screening technology to identify compounds that could be optimized as small molecule cancer drugs, Frost Biologic has a decade-long track record of successfully reaching drug discovery milestones with minimal resources.
The legacy of this work is FROST450, a clinical candidate being prepared for clinical trials in oncology. Frost Biologic is preparing to launch Phase I clinical trials of FROST450 with a focus on gastric cancer.
Frost remains privately owned and funded.